Literature DB >> 1489732

T cell activation and thymic tolerance induction require different adhesion intensities of the CD8 co-receptor.

M Knobloch1, G Schönrich, J Schenkel, M Malissen, B Malissen, A M Schmitt-Verhulst, G J Hämmerling, B Arnold.   

Abstract

Activation of mature lymphocytes requires in addition to the TCR contact with the corresponding antigen the binding of the CD8 or CD4 co-receptors to MHC class I or class II proteins respectively. To investigate the contribution of the CD8-class I interaction to the elimination of autoreactive T cells during negative selection in the thymus we generated two types of transgenic mice. One set expressed a modified Kb molecule which contained a human HLA-A2 alpha 3 domain, thereby missing the binding residues for the murine CD8 molecules. The second set of mice expressed an anti-Kb specific TCR. Both lines were crossed and in the resulting double transgenic mice the development of Kb-reactive T cells was followed with an anti-clonotypic antibody. Surprisingly, efficient clonal deletion in the thymus was still observed, although the reduced CD8-class I adhesion abrogated effector functions in vivo and in vitro. These results imply that even T cells with intermediate affinity for self are negatively selected in the thymus despite the fact that they are not able to react against self antigens in the periphery. Thus a safety window is created which decreases the risk of autoaggression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489732     DOI: 10.1093/intimm/4.10.1169

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  2 in total

1.  Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice.

Authors:  G Strauss; D A Vignali; G Schönrich; G J Hämmerling
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

2.  T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity.

Authors:  Dietmar Zehn; Michael J Bevan
Journal:  Immunity       Date:  2006-08-03       Impact factor: 31.745

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.